Format

Send to

Choose Destination
J Am Acad Dermatol. 2019 May;80(5):1322-1331. doi: 10.1016/j.jaad.2018.03.011. Epub 2018 Mar 17.

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT.

Author information

1
Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
2
Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea; Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
3
Biomedical Research Institute, Pusan National University Hospital, Busan, Korea; Department of Nuclear Medicine, Pusan National University Hospital, Busan, Korea.
4
Department of Statistics, Hallym University, Chuncheon, Korea.
5
Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
6
Department of Nuclear Medicine, Pusan National University Hospital, Busan, Korea; Department of Nuclear Medicine, College of Medicine, Pusan National University, Busan, Korea; Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea. Electronic address: growthkim@daum.net.

Abstract

BACKGROUND:

Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease.

OBJECTIVE:

To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT).

METHODS:

Patients with psoriasis and healthy controls underwent baseline 18F-FDG PET/CT imaging. Patients with moderate-to-severe psoriasis were treated with ustekinumab and underwent 18F-FDG PET/CT again after a Psoriasis Area and Severity Index of 75 was achieved.

RESULTS:

After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P < .05).

LIMITATIONS:

Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population.

CONCLUSION:

Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.

KEYWORDS:

PET/CT; cardiovascular disease; metabolic syndrome; positron emission tomography–computed tomography; psoriasis; ustekinumab

PMID:
29559399
DOI:
10.1016/j.jaad.2018.03.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center